Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NEWS -- RG6501 (OpRegen®) Full Phase 1/2a Results to Be Featured at 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Allen C. Ho, M.D., FACS
CARLSBAD, Calif., March 14, 2022--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that full results from a Phase 1/2a clinical study of RG6501 (OpRegen®), a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD), will be presented at the 2022 Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2022) (https://www.arvo.org/annual-meeting/), to be held May 1 – 4, 2022 at the Colorado Convention Center in Denver, CO. The presentation, "Safety and Efficacy of a Phase 1/2a Clinical Trial of Transplanted Allogeneic Retinal Pigmented Epithelium (RPE, OpRegen) Cells in Advanced Dry Age-Related Macular Degeneration (AMD)" will be featured as part of the Retinal Prostheses and Transplantation Session, on May 2, 2022 between 3:00 PM to 5:00 PM MDT, by Allen C. Ho, M.D., FACS, Wills Eye Hospital Attending Surgeon and Director of Retina Research, Professor of Ophthalmology, Thomas Jefferson University, Mid Atlantic Retina and President, The Retina Society (abstract number 3714956). RG6501 (OpRegen) is currently being developed under an exclusive worldwide collaboration between Lineage, Roche and Genentech, a member of the Roche Group.
The Association for Research in Vision and Ophthalmology, Inc. (ARVO) was founded in 1928 in Washington, DC, by a group of 73 ophthalmologists. ARVO is the largest and most respected eye and vision research organization in the world. ARVO members include nearly 11,000 researchers from over 75 countries. ARVO advances research worldwide into understanding the visual system and preventing, treating and curing its disorders. For more information, please visit https://www.arvo.org/ or follow the association on Twitter @ARVOInfo.
About OpRegen
OpRegen® is a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, being developed under a worldwide collaboration between Lineage, Roche and Genentech, a member of the Roche Group. The Phase 1/2a open-label, dose escalation safety and efficacy study evaluated a single injection of human retinal pigment epithelium cells derived from an established pluripotent cell line and transplanted subretinally in patients with advanced dry AMD with GA and enrolled 24 patients into 4 cohorts. The first 3 cohorts enrolled only legally blind patients with a best corrected visual acuity (BCVA) of 20/200 or worse. The fourth cohort enrolled 12 better vision patients (BCVA from 20/65 to 20/250 with smaller mean areas of GA). Cohort 4 also included patients treated with a new "thaw-and-inject" formulation of OpRegen, which can be shipped directly to sites and used immediately upon thawing, removing the complications and logistics of having to use a dose preparation facility. The primary objective of the study was to evaluate the safety and tolerability of OpRegen as assessed by the incidence and frequency of treatment emergent adverse events. Secondary objectives are to evaluate the preliminary efficacy of OpRegen treatment by assessing the changes in ophthalmological parameters measured by various methods of primary clinical relevance. OpRegen has been well tolerated to date and there have been no new, unexpected ocular or systemic adverse events or serious adverse events related to OpRegen or study procedures that have not been previously reported.
About Dry AMD
Dry age-related macular degeneration (AMD) is a leading cause of adult blindness in the developed world. There are two forms of AMD: wet AMD and dry AMD. Dry AMD is the more common of the two types, accounting for approximately 85-90% of cases. Wet AMD is the less common of the two types, accounting for approximately 10-15% of cases. Global sales of the two leading wet AMD therapies were in excess of $10 billion in 2019. Nearly all cases of wet AMD begin as dry AMD. Dry AMD typically affects both eyes. There are currently no U.S. Food and Drug Administration (FDA) or European Medicines Agency (EMA) approved treatment options available for patients with dry AMD.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic ("off-the-shelf") product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer. For more information, please visit https://www.lineagecell.com or follow the Company on Twitter @LineageCell.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220314005160/en/
Contacts
Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
mailto://ir@lineagecell.com
(442) 287-8963
Solebury Trout IR
Mike Biega
mailto://Mbiega@soleburytrout.com
(617) 221-9660
Russo Partners – Media Relations
Nic Johnson or David Schull
mailto://Nic.johnson@russopartnersllc.com
mailto://David.schull@russopartnersllc.com
(212) 845-4242
NEWS -- Tokens.com Expands Virtual Real Estate Portfolio With Acquisition in NFT World Metaverse
TORONTO, March 14, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in Web3 crypto assets and businesses linked to the Metaverse and NFTs, is pleased to share that its subsidiary, Metaverse Group, has purchased virtual NFT real estate in the NFT Worlds Metaverse.
NFT Worlds is a fully decentralized, fully customizable, community driven, play to earn gaming platform where world owners can create their own limitless Metaverse games or experiences for players or exclusive communities within their worlds.
Currently using Minecraft and its sprawling open-source ecosystem, NFT Worlds builds on the backbone of decades worth of open source development within the Minecraft community and radically expands on it to enable entirely new types of 3D voxel-based, decentralized gaming Metaverses backed by the Ethereum blockchain.
Metaverse Group’s purchase expands and diversifies its eight-figure real estate portfolio. NFT World parcels are staking compatible which introduces a new revenue stream to Metaverse Group. This parcel brings new opportunities for Metaverse Group, its partners and parties interested in establishing a presence in the Metaverse. Each NFT World is an explorable, limitless world that can be developed into anything you can imagine. NFT World is unique as it is compatible with Minecraft, in addition to being massively multiplayer, and decentralized.
"Adding this parcel to our portfolio diversifies our offering across 7 different Metaverses," commented Andrew Kiguel, CEO of Tokens.com and Executive Chairman of Metaverse Group. "We understand the popularity of Minecraft and are pleased to own a parcel compatible with it."
Brands or virtual landowners interested in partnering with Metaverse Group should contact mailto://Info@metaversegroup.com.
About Tokens.com
Tokens.com Corp is a publicly traded Web3 company that owns an inventory of Metaverse, P2E, DeFi, and NFT based digital assets. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in Play-to-Earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, and YouTube.
About Metaverse Group
The Metaverse Group is a vertically integrated NFT based Metaverse real estate company. The group, with its global headquarters in Decentraland’s CryptoValley, also owns an eight figure real estate portfolio across many leading virtual worlds. The company intends to continue to purchase, develop and rent out its portfolio of real estate assets. Tokens.com, a publicly- traded company, is the majority owner of Metaverse Group.
For further information please visit https://metaversegroup.com.
About NFT World
NFT Worlds is a fully decentralized, fully customizable, community driven, play to earn gaming platform where world owners can create their own limitless Metaverse games or experiences for players or exclusive communities within their worlds.
Currently using Minecraft and it's sprawling open-source ecosystem, NFT Worlds builds on the backbone of decades worth of open source development within the Minecraft community and radically expands on it to enable entirely new types of 3D voxel-based, decentralized gaming Metaverses backed by the Ethereum blockchain.
For further information visit: https://www.nftworlds.com/
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220314005101/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
+1-647-578-7490
mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
mailto://contact@tokens.com
Media: Ryleigh Ebron – Talk Shop Media
mailto://ryleigh@talkshopmedia.com
NEWS -- Tokens.com Expands Virtual Real Estate Portfolio With Acquisition in NFT World Metaverse
TORONTO, March 14, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in Web3 crypto assets and businesses linked to the Metaverse and NFTs, is pleased to share that its subsidiary, Metaverse Group, has purchased virtual NFT real estate in the NFT Worlds Metaverse.
NFT Worlds is a fully decentralized, fully customizable, community driven, play to earn gaming platform where world owners can create their own limitless Metaverse games or experiences for players or exclusive communities within their worlds.
Currently using Minecraft and its sprawling open-source ecosystem, NFT Worlds builds on the backbone of decades worth of open source development within the Minecraft community and radically expands on it to enable entirely new types of 3D voxel-based, decentralized gaming Metaverses backed by the Ethereum blockchain.
Metaverse Group’s purchase expands and diversifies its eight-figure real estate portfolio. NFT World parcels are staking compatible which introduces a new revenue stream to Metaverse Group. This parcel brings new opportunities for Metaverse Group, its partners and parties interested in establishing a presence in the Metaverse. Each NFT World is an explorable, limitless world that can be developed into anything you can imagine. NFT World is unique as it is compatible with Minecraft, in addition to being massively multiplayer, and decentralized.
"Adding this parcel to our portfolio diversifies our offering across 7 different Metaverses," commented Andrew Kiguel, CEO of Tokens.com and Executive Chairman of Metaverse Group. "We understand the popularity of Minecraft and are pleased to own a parcel compatible with it."
Brands or virtual landowners interested in partnering with Metaverse Group should contact mailto://Info@metaversegroup.com.
About Tokens.com
Tokens.com Corp is a publicly traded Web3 company that owns an inventory of Metaverse, P2E, DeFi, and NFT based digital assets. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in Play-to-Earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, and YouTube.
About Metaverse Group
The Metaverse Group is a vertically integrated NFT based Metaverse real estate company. The group, with its global headquarters in Decentraland’s CryptoValley, also owns an eight figure real estate portfolio across many leading virtual worlds. The company intends to continue to purchase, develop and rent out its portfolio of real estate assets. Tokens.com, a publicly- traded company, is the majority owner of Metaverse Group.
For further information please visit https://metaversegroup.com.
About NFT World
NFT Worlds is a fully decentralized, fully customizable, community driven, play to earn gaming platform where world owners can create their own limitless Metaverse games or experiences for players or exclusive communities within their worlds.
Currently using Minecraft and it's sprawling open-source ecosystem, NFT Worlds builds on the backbone of decades worth of open source development within the Minecraft community and radically expands on it to enable entirely new types of 3D voxel-based, decentralized gaming Metaverses backed by the Ethereum blockchain.
For further information visit: https://www.nftworlds.com/
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220314005101/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
+1-647-578-7490
mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
mailto://contact@tokens.com
Media: Ryleigh Ebron – Talk Shop Media
mailto://ryleigh@talkshopmedia.com
NEWS -- Tokens.com Announces Lease Agreement with Skechers on its Fashion Street Estate
TORONTO, March 10, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in Web3 crypto assets and businesses linked to the Metaverse and NFTs, is pleased to announce that its subsidiary company Metaverse Group has signed a lease agreement with Skechers USA, Inc. (NYSE: SKX), the third largest athletic footwear brand in the world.
Skechers has leased the equivalent of a 5,000-square-foot space on virtual land owned by Metaverse Group to build an experiential store on the Fashion Street Estate located in the Decentraland Metaverse.
"Our collaboration with Skechers marks a pivotal evolution in our Metaverse strategy. This partnership establishes our subsidiary, Metaverse Group, as one of the first virtual landlords to successfully lease out its Metaverse real estate," commented Andrew Kiguel, Tokens.com CEO and Metaverse Group Executive Chairman. "We not only own valuable virtual real estate but also generate recurring revenue, similar to landlords in the physical world and online advertising platforms such as large search engines and social media networks."
"Our Decentraland agreement is an investment in our future," said Michael Greenberg, president of Skechers. "We look forward to embarking on this virtual era, and exploring creative ways for our brand to engage with new customers and audiences as we launch the new Skechers experience."
Brands seeking to participate in the Metaverse or landowners seeking to sell virtual land are encouraged to reach out to mailto://landsales@metaversegroup.com for more information.
About Tokens.com
Tokens.com Corp is a publicly traded Web3 company that owns an inventory of Metaverse, P2E, DeFi and NFT based digital assets. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in Play-to-Earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities at Twitter, LinkedIn, and YouTube.
About Metaverse Group
The Metaverse Group is a vertically integrated NFT based metaverse real estate company. The group, with its global headquarters in Decentraland’s Crypto Valley, also owns an eight-figure real estate portfolio across many leading virtual worlds. The company intends to continue to purchase, develop and rent out its portfolio of real estate assets. Tokens.com, a publicly- traded company, is the majority owner of Metaverse Group.
For further information please visit https://metaversegroup.com
About SKECHERS USA, Inc.
Skechers USA, Inc. (NYSE:SKX), The Comfort Technology Company™ based in Southern California, designs, develops and markets a diverse range of lifestyle and performance footwear, apparel and accessories for men, women and children. The Company’s collections are available in the United States and over 180 countries and territories via department and specialty stores, and direct to consumers through 4,306 Company and third-party-owned retail stores and e-commerce websites. The Company manages its international business through a network of global distributors, joint venture partners in Asia, Israel and Mexico, and wholly-owned subsidiaries in Canada, Japan, India, Europe and Latin America. For more information, please visit https://about.skechers.com and follow us on Facebook, Instagram, Twitter, and TikTok.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may," "will," "plan," "expect," "anticipate," "estimate," "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220310005614/en/
Contacts
For further information:
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ryleigh Ebron – Talk Shop Media
Email: mailto://ryleigh@talkshopmedia.com
NEWS -- Tokens.com Announces Lease Agreement with Skechers on its Fashion Street Estate
TORONTO, March 10, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in Web3 crypto assets and businesses linked to the Metaverse and NFTs, is pleased to announce that its subsidiary company Metaverse Group has signed a lease agreement with Skechers USA, Inc. (NYSE: SKX), the third largest athletic footwear brand in the world.
Skechers has leased the equivalent of a 5,000-square-foot space on virtual land owned by Metaverse Group to build an experiential store on the Fashion Street Estate located in the Decentraland Metaverse.
"Our collaboration with Skechers marks a pivotal evolution in our Metaverse strategy. This partnership establishes our subsidiary, Metaverse Group, as one of the first virtual landlords to successfully lease out its Metaverse real estate," commented Andrew Kiguel, Tokens.com CEO and Metaverse Group Executive Chairman. "We not only own valuable virtual real estate but also generate recurring revenue, similar to landlords in the physical world and online advertising platforms such as large search engines and social media networks."
"Our Decentraland agreement is an investment in our future," said Michael Greenberg, president of Skechers. "We look forward to embarking on this virtual era, and exploring creative ways for our brand to engage with new customers and audiences as we launch the new Skechers experience."
Brands seeking to participate in the Metaverse or landowners seeking to sell virtual land are encouraged to reach out to mailto://landsales@metaversegroup.com for more information.
About Tokens.com
Tokens.com Corp is a publicly traded Web3 company that owns an inventory of Metaverse, P2E, DeFi and NFT based digital assets. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in Play-to-Earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities at Twitter, LinkedIn, and YouTube.
About Metaverse Group
The Metaverse Group is a vertically integrated NFT based metaverse real estate company. The group, with its global headquarters in Decentraland’s Crypto Valley, also owns an eight-figure real estate portfolio across many leading virtual worlds. The company intends to continue to purchase, develop and rent out its portfolio of real estate assets. Tokens.com, a publicly- traded company, is the majority owner of Metaverse Group.
For further information please visit https://metaversegroup.com
About SKECHERS USA, Inc.
Skechers USA, Inc. (NYSE:SKX), The Comfort Technology Company™ based in Southern California, designs, develops and markets a diverse range of lifestyle and performance footwear, apparel and accessories for men, women and children. The Company’s collections are available in the United States and over 180 countries and territories via department and specialty stores, and direct to consumers through 4,306 Company and third-party-owned retail stores and e-commerce websites. The Company manages its international business through a network of global distributors, joint venture partners in Asia, Israel and Mexico, and wholly-owned subsidiaries in Canada, Japan, India, Europe and Latin America. For more information, please visit https://about.skechers.com and follow us on Facebook, Instagram, Twitter, and TikTok.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may," "will," "plan," "expect," "anticipate," "estimate," "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220310005614/en/
Contacts
For further information:
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ryleigh Ebron – Talk Shop Media
Email: mailto://ryleigh@talkshopmedia.com
NEWS -- Oncolytics Biotech® Announces Phase 1b Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Proteasome Inhibitor Combination in Multiple Myeloma in an Abstract at the AACR Annual Meeting
NEWS -- Oncolytics Biotech® Announces Upcoming Poster Presentation at the AACR Annual Meeting
SAN DIEGO, Calif. and CALGARY, AB, March 9, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced an upcoming poster presentation that will feature long-term follow-up results from ReoGlio, an investigator-sponsored, phase 1b trial evaluating the combination of pelareorep and granulocyte-macrophage colony-stimulating factor (GM-CSF) alongside standard chemoradiotherapy and adjuvant temozolomide for the treatment of glioblastoma multiforme (GBM). The poster will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022, which is taking place both virtually and in-person at the Ernest N. Morial Convention Center in New Orleans from April 8-13, 2022.
Details on the poster and corresponding abstract are shown below.
Poster Title: Combination of reovirus (pelareorep) and granulocyte-macrophage colony-stimulating factor (GM-CSF) alongside standard chemoradiotherapy and adjuvant chemotherapy (temozolomide) for patients with glioblastoma multiforme (GBM): Long term follow up results of the ReoGlio phase Ib trial
Session Title: Phase I Clinical Trials 2
Abstract Number: CT194
Oncolytics will provide details on the results described in this abstract following publication of the abstract and corresponding poster at the AACR Annual Meeting in April, in accordance with conference embargo policies regarding clinical trials abstracts.
About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards a registration study in metastatic breast cancer. For further information, please visit: https://www.oncolyticsbiotech.com.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements, including the Company's belief as to the potential and mode of action of pelareorep as a cancer therapeutic; the timing and anticipated subject matter of the upcoming presentations of clinical and preclinical study data and the timing thereof; Oncolytics' plans and expectations as to the purpose, design, outcomes and benefits of its current or pending clinical trials involving pelareorep; our plans to advance towards a registration study in metastatic cancer; and other statements related to anticipated developments in the Company's business and technologies involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. In particular, we may be impacted by business interruptions resulting from COVID-19 coronavirus, including operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labour shortages, travel and shipping disruption and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how the Company may be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.
Company Contact
Jon Patton
Director of IR & Communication
+1-858-886-7813
mailto://jpatton@oncolytics.ca
Investor Relations for Oncolytics
Timothy McCarthy
LifeSci Advisors
+1-917-679-9282
mailto://tim@lifesciadvisors.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/oncolytics-biotech-announces-upcoming-poster-presentation-at-the-aacr-annual-meeting-301498760.html
SOURCE Oncolytics Biotech® Inc.
NEWS -- FuelPositive Announces Appointment of Derek Boudreau as Strategic Advisor, Agricultural Implementation
TORONTO, March 08, 2022 (GLOBE NEWSWIRE) -- FuelPositive Corporation (TSX.V: NHHH) (OTCQB: NHHHF) (“FuelPositive” or the “Company”) is pleased to announce that Derek P. Boudreau has joined the Company as Strategic Advisor, Agricultural Implementation. Derek brings over 27 years of global experience in the off-highway equipment business, gained at John Deere Company, which is a world leader in agricultural, construction and forestry machinery, internal combustion engines, drivetrains (used in heavy equipment), and lawn care equipment.
Originally from Canada, Derek’s experience spans the areas of sales, marketing, product engineering, product support and operations management, as well as global product line leadership. Derek developed a broad global perspective as he successfully led businesses for John Deere in Canada, the U.S., Russia and Finland. He has a strong track record of profitably growing businesses in the agricultural, construction and forestry equipment sectors. Derek has a passion for expanding product offerings to better serve customers through organic development and strategic partnerships. He holds a BEng (McGill University) and an MBA (University of Chicago).
“We are thrilled to have Derek on our team. His vast experience working in sales, management, manufacturing and distribution with agricultural equipment and internal combustion engines, will help ensure FuelPositive makes the best possible decisions related to the broad range of agricultural opportunities presenting themselves to the Company every day. He is starting off reviewing our intellectual property and working with farmers to build our understanding of their practices, preferences and requirements. His knowledge will play a critical role as we determine and maximize the impact our on-site green ammonia production systems will have on farms and in other applications as we grow,” said Ian Clifford, CEO and Board Chair of FuelPositive.
“I’m excited to be joining this team of exceptional people who have been hand-picked to achieve FuelPositive’s mission. I look forward to supporting our agricultural producers and I’m grateful for the opportunity to apply my knowledge to a cause that is directed at reducing pollution and enabling a greener world,” said Derek Boudreau.”
About FuelPositive
FuelPositive is a Canadian growth-stage technology company committed to providing commercially viable and sustainable “cradle to cradle” clean technology solutions, including green ammonia (NH3), for use across a broad spectrum of industries and applications.
By focusing on technologies that are clean, sustainable and economically advantageous/realizable, the Company aims to change the course of climate change through practical solutions that can be implemented now.
The Company’s core technology, a modular and scalable green ammonia system, takes air, water and sustainable electricity and synthesizes it into a non-polluting chemical for multiple applications, including fertilizer for farming, fuel for internal combustion engines and a solution for grid storage.
FuelPositive systems are designed to provide for green ammonia production on-site, where it’s needed. This eliminates precarious supply chains and creates end-user security.
Green ammonia is being considered as a replacement for fossil fuels and as a key enabler of the hydrogen economy.
The company’s most recent corporate update can be found here (https://fuelpositive.com/filing-of-annual-audited-financial-statements/).
Cautionary Statement
Trading in the securities of the Company should be considered highly speculative. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains certain “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) that are based on expectations, estimates and projections as at the date of this news release. The information in this release about future plans and objectives of the Company, including the expected expenditures of the proceeds of the private placement, are forward-looking statements.
These forward-looking statements are based on assumptions and estimates of management of the Company at the time they were made and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect.
Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
Forward-looking information is provided for the purpose of providing information about management’s expectations and plans relating to the future. The Company disclaims any intention or obligation to update or revise any forward-looking information or to explain any material difference between subsequent actual events and such forward-looking information, except to the extent required by applicable law.
For Media or Investor enquiries, please contact:
Ian Clifford
Chief Executive Officer and Board Chair
mailto://mailbox1@fuelpositive.com
https://www.fuelpositive.com
Investor Relations (United States)
RBMG – RB Milestone Group LLC
Trevor Brucato, Managing Director
mailto://fuelpositive@rbmilestone.com
https://www.rbmilestone.com
NEWS -- Tokens.com Announces that it has Staked its CryptoPunk
TORONTO, March 08, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in Web3 crypto assets and businesses linked to the Metaverse and NFTs, is pleased to announce that The Company has staked its recently acquired CryptoPunk #5067, using the NFTX platform.
NFTX is an NFT DeFi platform that enables users to borrow, lend, and trade various top NFTs. Depositors like Tokens.com can stake their CryptoPunk or other digital assets for yield. Yield is paid in additional tokens.
Trading generates fees for users that have deposited into the vault. The fees are split between the members of the vault based on the percentage of their total capital allocation. The current annualized yield for depositing a CryptoPunk into an NFTX vault is over 17%.
"Using the NFTX platform to stake our CryptoPunk opens a new revenue stream for Tokens.com. We are happy to use and explore new DeFi applications and continue to bring shareholders the most exciting aspects of Web3," said Andrew Kiguel, Tokens.com CEO.
"NFTX is an innovator in the DeFi space and is taking steps to create more liquidity in the NFT ecosystem. We are big believers in the macro growth potential for DeFi and NFTs and think this is just part of a large trend of increased liquidity for NFT holders. We anticipate this will further increase demand for top NFT projects like CryptoPunks," commented Deven Soni, COO of Tokens.com.
About Tokens.com
Tokens.com Corp is a publicly-traded Web3 company that owns an inventory of Metaverse, P2E, DeFi and NFT based digital assets and businesses. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in Play-to-Earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, and YouTube.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220308005354/en/
Contacts
For further information:
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ryleigh Ebron – Talk Shop Media
Email: mailto://ryleigh@talkshopmedia.com
NEWS -- Tokens.com Announces that it has Staked its CryptoPunk
TORONTO, March 08, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in Web3 crypto assets and businesses linked to the Metaverse and NFTs, is pleased to announce that The Company has staked its recently acquired CryptoPunk #5067, using the NFTX platform.
NFTX is an NFT DeFi platform that enables users to borrow, lend, and trade various top NFTs. Depositors like Tokens.com can stake their CryptoPunk or other digital assets for yield. Yield is paid in additional tokens.
Trading generates fees for users that have deposited into the vault. The fees are split between the members of the vault based on the percentage of their total capital allocation. The current annualized yield for depositing a CryptoPunk into an NFTX vault is over 17%.
"Using the NFTX platform to stake our CryptoPunk opens a new revenue stream for Tokens.com. We are happy to use and explore new DeFi applications and continue to bring shareholders the most exciting aspects of Web3," said Andrew Kiguel, Tokens.com CEO.
"NFTX is an innovator in the DeFi space and is taking steps to create more liquidity in the NFT ecosystem. We are big believers in the macro growth potential for DeFi and NFTs and think this is just part of a large trend of increased liquidity for NFT holders. We anticipate this will further increase demand for top NFT projects like CryptoPunks," commented Deven Soni, COO of Tokens.com.
About Tokens.com
Tokens.com Corp is a publicly-traded Web3 company that owns an inventory of Metaverse, P2E, DeFi and NFT based digital assets and businesses. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in Play-to-Earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, and YouTube.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220308005354/en/
Contacts
For further information:
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ryleigh Ebron – Talk Shop Media
Email: mailto://ryleigh@talkshopmedia.com
NEWS -- Innovation Pharmaceuticals Reports Additional Findings Based on Review of Brilacidin Phase 2 COVID-19 Trial Results and Compassionate Use Cases
WAKEFIELD, MA / ACCESSWIRE / March 7, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today reported findings from data review of the Company's Brilacidin Phase 2 COVID-19 study and compassionate use of Brilacidin in critically-ill COVID-19 patients.
"Based on analyses of our Phase 2 trial results, Brilacidin showed promising treatment effects in NEWS2 clinical improvement scores and among patients with the most elevated biomarker levels," said Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. "These results, along with observations on the compassionate use of Brilacidin in COVID-19 related to dosing, as well as data being generated from ongoing scientific collaborations, are informing paths forward for our Brilacidin antiviral program. We believe Brilacidin has merit to help address COVID-19 and can play a role in preparing for future pandemics, given Brilacidin's unique immunomodulatory and antiviral properties. Progress in the Brilacidin antiviral program largely will be dependent upon obtaining government funding for additional clinical development and leveraging external research relationships. Going forward, our business focus will be to advance Brilacidin in other disease areas and to pursue new business opportunities through joint ventures and other investments."
Summary of Brilacidin COVID-19 Trial Design and Results
The Phase 2 trial (see NCT04784897) was a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of Brilacidin treatment in addition to current standard-of-care (SoC) compared to SoC alone, in 120 hospitalized patients with moderate-to-severe COVID-19.
Study treatment, Brilacidin IV or saline IV (placebo), was administered as 3 doses or 5 doses. For efficacy analyses, the main comparison was between the Brilacidin 5-dose group and the pooled placebo group.
Even with randomization--stratified by age (<= 65 yrs, >65 yrs) and severity (moderate, severe)--patients allocated to the Brilacidin treatment groups exhibited a greater degree of disease burden at baseline, as reflected by higher, on average, elevated biomarker levels (e.g., CRP, viral load), in contrast to the pooled placebo group.
As previously released, Brilacidin did not show a difference compared to placebo in reducing Time to Sustained Recovery Through Day 29, the study's primary endpoint based on clinical status. There was also no difference in mortality between active and placebo, with both groups experiencing low mortality rates (7 percent) compared to other studies that evaluated patients with moderate-to-severe COVID-19. Beneficial Brilacidin treatment effects, however, were observed in NEWS2 secondary endpoints, as well as on the primary endpoint in patient subgroups, as summarized below.
Pharmacokinetic (PK) analysis (from measured plasma sample concentrations) provided comparable estimations to those seen previously in the Brilacidin IV program, although exposure was generally greater than observed prior (when comparing patients on similar treatment regimens for the indication of acute bacterial skin and skin structure infections [ABSSSI]). These new PK data will help inform any future Brilacidin IV dosing strategies.
Brilacidin was generally well-tolerated by patients, with an overall safety profile in COVID-19 patients consistent with previous clinical studies. The incidence of patients with at least one treatment-emergent adverse event (TEAE) was higher for Brilacidin treatment compared to placebo. However, the proportion of patients with TEAEs is similar across groups (72 percent on active, 65 percent on placebo) after excluding the Brilacidin-related adverse events of tingling (paresthesia) and hypoesthesia (numbness), which are known, transient, mostly mild, non-serious adverse events related to Brilacidin IV treatment. The incidence of serious adverse events was the same (12 percent on active, 12 percent on placebo), and no serious adverse events were reported as related to study treatment.
Secondary Endpoint Analysis
More patients in the Brilacidin 5-dose group achieved and maintained, for at least 24 hours, a National Early Warning Score 2 (NEWS2) of <=2. By 10 days (from randomization), 97 percent of the Brilacidin 5-dose group had achieved this NEWS2 endpoint compared to 84 percent of patients in the pooled placebo group. A NEWS2 score of 2 or less is clinically meaningful as an aggregate score of 4 or less translates to low clinical risk, per NEWS2 criteria.
The mean change from baseline in NEWS2 was greater for the Brilacidin treatment groups than for the pooled placebo group, at all assessment timepoints (Study Days 3, 5, 8, 11, 15, and 29).
NEWS2 is an ordinal scale developed by the U.K.'s Royal College of Physicians to identify patients at risk for rapid clinical deterioration requiring critical care intervention and is considered a valuable tool for management of COVID-19. NEWS2 is based on certain physiological parameters--respiration rate, oxygen saturation, supplemental oxygen, systolic blood pressure, pulse, level of consciousness, and temperature. NEWS2 has been used as an endpoint for several COVID-19 clinical trials.
Post-Hoc Analysis
NEWS -- Plus Therapeutics Announces Upcoming Participation at the 2022 SNMMI Therapeutics Conference
AUSTIN, Texas, March 03, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will sponsor and present an industry satellite symposium at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Therapeutics Conference, being held in-person March 10-12, 2022 at the Hyatt Regency, New Orleans, Louisiana.
Details of the symposium are as follows:
Title: Radiolabeled NanoLiposomes: A Novel Targeted Treatment for Rare and Central Nervous System Cancers
Date: March 12, 2022 at 7:15 – 8:00 a.m. CT
Location: Hyatt Regency, Elite B Main Meeting Room, New Orleans, Louisiana
Presenter: Norman LaFrance, MD, ME, FACP, FACNP, FACNM; Chief Medical Officer and Senior Vice President at Plus Therapeutics
A copy of the presentation will be made available under the Presentations tab of the Investors section of the Company’s website following the symposium at https://ir.plustherapeutics.com.
About Plus Therapeutics, Inc.
Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company focused on developing innovative, targeted radiotherapeutics for adults and children worldwide with rare and difficult-to-treat cancers. Our proprietary radiotherapeutic platform uniquely uses nanoliposomes to encapsulate and deliver the radioisotope, Rhenium, into or near a tumor via a single, direct infusion. The lead radiotherapeutic in our pipeline, Rhenium-186 NanoLiposome (186RNL), is being evaluated in U.S. multi-center clinical trials for the treatment of recurrent glioblastoma and leptomeningeal metastases. More information may be found at https://PlusTherapeutics.com and https://ReSPECT-Trials.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “designed to,” “will,” “can,” “potential,” “focus,” “preparing,” “next steps,” “possibly,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of 186RNL including the ability of 186RNL to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-LM or the ReSPECT-PBC trials; possible negative effects of 186RNL; the continued evaluation of 186RNL including through evaluations via a seventh patient cohort; and the intended functions of the Company’s platform and expected benefits from such functions.
The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the regenerative medicine field, among others; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Peter Vozzo
Westwicke/ICR
(443) 377-4767
mailto://Peter.Vozzo@westwicke.com
Media Contact
Terri Clevenger
Westwicke/ICR
(203) 856-4326
mailto://Terri.Clevenger@westwicke.com
NEWS -- Tokens.com Announces First Metaverse Tenants
TORONTO, March 02, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in Web3 crypto assets and businesses linked to the Metaverse and NFTs, is pleased to announce that its subsidiary, Metaverse Group, has signed virtual land lease agreements with Groundbreak Ventures, Renno & Co. Inc., Sophia Technologies, and Thrivo Technologies Inc.
In addition to the lease agreements, tenants will be using Metaverse Group’s development and architectural services to assist with the development of their Metaverse projects.
"These lease agreements mark a pivotal evolution in our Metaverse strategy. Not only do we own valuable virtual real estate but we also generate recurring revenue, similar to landlords in the physical world and to online advertising platforms such as large search engines and social media networks," commented Tokens.com CEO and Metaverse Group Executive Chairman, Andrew Kiguel. "These partnerships establish Metaverse Group as one of the first virtual landlords in the world to successfully lease out its Metaverse real estate."
The tenants are renting virtual real estate on various parcels across Metaverse Group’s portfolio in Decentraland and waterfront parcels within Somnium Space.
"Signing these initial leases for virtual real estate solidifies our position as Metaverse landlords. We are in active discussion with numerous other parties and are looking forward to launching more brands into the Metaverse this year," commented Lorne Sugarman, CEO of Metaverse Group.
This collection of tenants come from diverse backgrounds:
NEWS -- Tokens.com Announces First Metaverse Tenants
TORONTO, March 02, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in Web3 crypto assets and businesses linked to the Metaverse and NFTs, is pleased to announce that its subsidiary, Metaverse Group, has signed virtual land lease agreements with Groundbreak Ventures, Renno & Co. Inc., Sophia Technologies, and Thrivo Technologies Inc.
In addition to the lease agreements, tenants will be using Metaverse Group’s development and architectural services to assist with the development of their Metaverse projects.
"These lease agreements mark a pivotal evolution in our Metaverse strategy. Not only do we own valuable virtual real estate but we also generate recurring revenue, similar to landlords in the physical world and to online advertising platforms such as large search engines and social media networks," commented Tokens.com CEO and Metaverse Group Executive Chairman, Andrew Kiguel. "These partnerships establish Metaverse Group as one of the first virtual landlords in the world to successfully lease out its Metaverse real estate."
The tenants are renting virtual real estate on various parcels across Metaverse Group’s portfolio in Decentraland and waterfront parcels within Somnium Space.
"Signing these initial leases for virtual real estate solidifies our position as Metaverse landlords. We are in active discussion with numerous other parties and are looking forward to launching more brands into the Metaverse this year," commented Lorne Sugarman, CEO of Metaverse Group.
This collection of tenants come from diverse backgrounds:
NEWS -- Nanomix Completes 1-for-173 Reverse Stock Split
EMERYVILLE, Calif., March 02, 2022--(BUSINESS WIRE)--Nanomix Corporation (OTCBB: NNMX) ("Nanomix" or the "Company"), a leader in the development of mobile, affordable, point-of-care diagnostics, today announced it has completed the previously announced reverse stock split of its outstanding shares of common stock at a ratio of 1-for-173. The reverse stock split was announced on June 29, 2021 in conjunction with the reverse merger with Boston Therapeutics.
The Company’s common stock will open for trading on Tuesday, March 2, 2022 on a post-split basis under the temporary trading symbol "NNMXD". The trading symbol will revert to "NNMX" after 20 business days.
Trading of the Company’s common stock will continue on a split-adjusted basis under a new CUSIP number. Based on the number of shares outstanding as of March 1, 2022, the reverse stock split reduced the number of shares of the Company’s common stock outstanding from approximately 917 million pre-reverse split to approximately 5.3 million post-reverse split.
All outstanding preferred shares, stock options, warrants and equity incentive plans immediately prior to the reverse stock split generally were appropriately adjusted by dividing the number of shares of common stock into which the preferred shares, stock options, warrants and equity incentive plans were exercisable or convertible by 173 and multiplying the exercise or conversion price by 173, as a result of the reverse stock split.
"We are pleased with the successful completion of this reverse stock split. Not only does this announcement mark the completion of the reverse merger process, but it also increases visibility of our stock to wider investor audiences. With this reverse stock split now complete, we can proceed with our growth strategy of the Company," stated David Ludvigson, President and Chief Executive Officer of Nanomix.
About Nanomix Corporation
Nanomix is the leader in the development of mobile point-of-care diagnostics with its Nanomix eLab platform and assays that provide rapid, accurate, quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The company’s products are designed to broadly impact healthcare delivery by bringing diagnostics to the point of initial patient interaction, whether in the hospital or in pre-hospital, remote or alternate-care settings, with the goal to enable faster clinical decision-making and potentially treatment-in-place. Nanomix’s first assay addresses the critical need for faster diagnosis of critical infections. The company is developing a pipeline of other tests designed to improve patient outcomes by making high-quality diagnostic information available within minutes. For more information, visit https://www.nano.com.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Forward looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company’s ongoing and planned product development; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section entitled "Risk Factors" in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220302005435/en/
Contacts
LHA Investor Relations
Tirth Patel
212-201-6614
mailto://tpatel@lhai.com
NEWS -- Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on March 10, 2022
CARLSBAD, Calif., March 01, 2022--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its fourth quarter and full year 2021 financial and operating results on Thursday, March 10, 2022, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, March 10, 2022, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2021 financial and operating results and to provide a business update.
Interested parties may access the conference call by dialing (866) 888-8633 from the U.S. and Canada and (636) 812-6629 from elsewhere outside the U.S. and Canada and should request the "Lineage Cell Therapeutics Call". A live webcast of the conference call will be available online in the Investors section (https://investor.lineagecell.com/events-and-presentations/upcoming-events) of Lineage’s website. A replay of the webcast will be available on Lineage’s website for 30 days and a telephone replay will be available through March 18, 2022, by dialing (855) 859-2056 from the U.S. and Canada and (404) 537-3406 from elsewhere outside the U.S. and Canada and entering conference ID number 7718167.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic ("off-the-shelf") product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, which is now being developed (https://investor.lineagecell.com/news-releases/news-release-details/lineage-establishes-exclusive-worldwide-collaboration-genentech) under a worldwide collaboration with Roche and Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer. For more information, please visit https://www.lineagecell.com or follow the Company on Twitter @LineageCell.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220301005049/en/
Contacts
Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(mailto://ir@lineagecell.com)
(442) 287-8963
Solebury Trout IR
Mike Biega
(mailto://Mbiega@soleburytrout.com)
(617) 221-9660
Russo Partners – Media Relations
Nic Johnson or David Schull
mailto://Nic.johnson@russopartnersllc.com
mailto://David.schull@russopartnersllc.com
(212) 845-4242
NEWS -- Tokens.com & Decentraland Announce Brands Participating in Metaverse Fashion Week
TORONTO, February 25, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in Web3 crypto assets and businesses linked to the Metaverse and NFTs, is pleased to share that Cavalli, Dolce & Gabbana, Elie Saab, Etro, Jacob & Co., and Tommy Hilfiger, amongst others, have joined the official lineup for the first-ever Metaverse Fashion Week.
The event will be held on property owned by Tokens.com’s subsidiary, Metaverse Group (https://metaversegroup.com/) and leased to Decentraland as the host. The event will take place from March 24th to March 27th. Brands are scheduled to host immersive virtual fashion shows featuring avatar models, runways, pop-up shops, and afterparties. Similar to physical global Fashion Weeks, this event will host a range of events, presentations and installations in addition to runway shows.
"Fashion is a key driver of interest in the Metaverse and we are pleased to have such a high caliber of brands participating in the first-ever Metaverse Fashion Week. The event provides brands the opportunity to showcase NFTs and virtual products while expanding their consumer reach to a new demographic," commented Andrew Kiguel, Tokens.com CEO and Metaverse Group Executive Chairman.
Metaverse Fashion Week will be free to attend and does not require specialized VR hardware. Additional information about Metaverse Fashion Week can be found on Vogue Business (https://www.voguebusiness.com/technology/paco-rabanne-dandg-and-etro-to-appear-at-metaverse-fashion-week).
As a publicly-traded company, Tokens.com offers its shareholders exposure to the fastest and most exciting areas of Web3, including Metaverse real estate ownership.
Subscribe (https://www.tokens.com/#newsletter) to receive the latest company developments.
About Metaverse Group
The Metaverse Group is a vertically integrated NFT based Metaverse real estate company. The group, with its global headquarters in Decentraland’s CryptoValley, also owns an eight-figure real estate portfolio across many leading virtual worlds. The company intends to continue to purchase, develop and rent out its portfolio of real estate assets. Tokens.com, a publicly-traded landowners company, is the majority owner of Metaverse Group.
For further information please visit https://metaversegroup.com.
Brands or virtual landowners interested in partnering with Metaverse Group should contact Info@metaversegroup.com.
About Decentraland
Decentraland is the first fully decentralized virtual world. Powered by DAO, which owns the most important smart contracts and assets of Decentraland. Decentraland is software running on Ethereum that seeks to incentivize a global network of users to operate a shared virtual world. Decentraland users can buy and sell digital real estate, while exploring, interacting and playing games within this virtual world.
For further information please visit https://decentraland.org
About Tokens.com
Tokens.com Corp is a publicly-traded Web3 company that owns an inventory of metaverse, P2E, DeFi and NFT based digital assets. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in Play-to-Earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, and YouTube.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220225005326/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ryleigh Ebron – Talk Shop Media
Email: mailto://ryleigh@talkshopmedia.com
NEWS -- Tokens.com & Decentraland Announce Brands Participating in Metaverse Fashion Week
TORONTO, February 25, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in Web3 crypto assets and businesses linked to the Metaverse and NFTs, is pleased to share that Cavalli, Dolce & Gabbana, Elie Saab, Etro, Jacob & Co., and Tommy Hilfiger, amongst others, have joined the official lineup for the first-ever Metaverse Fashion Week.
The event will be held on property owned by Tokens.com’s subsidiary, Metaverse Group (https://metaversegroup.com/) and leased to Decentraland as the host. The event will take place from March 24th to March 27th. Brands are scheduled to host immersive virtual fashion shows featuring avatar models, runways, pop-up shops, and afterparties. Similar to physical global Fashion Weeks, this event will host a range of events, presentations and installations in addition to runway shows.
"Fashion is a key driver of interest in the Metaverse and we are pleased to have such a high caliber of brands participating in the first-ever Metaverse Fashion Week. The event provides brands the opportunity to showcase NFTs and virtual products while expanding their consumer reach to a new demographic," commented Andrew Kiguel, Tokens.com CEO and Metaverse Group Executive Chairman.
Metaverse Fashion Week will be free to attend and does not require specialized VR hardware. Additional information about Metaverse Fashion Week can be found on Vogue Business (https://www.voguebusiness.com/technology/paco-rabanne-dandg-and-etro-to-appear-at-metaverse-fashion-week).
As a publicly-traded company, Tokens.com offers its shareholders exposure to the fastest and most exciting areas of Web3, including Metaverse real estate ownership.
Subscribe (https://www.tokens.com/#newsletter) to receive the latest company developments.
About Metaverse Group
The Metaverse Group is a vertically integrated NFT based Metaverse real estate company. The group, with its global headquarters in Decentraland’s CryptoValley, also owns an eight-figure real estate portfolio across many leading virtual worlds. The company intends to continue to purchase, develop and rent out its portfolio of real estate assets. Tokens.com, a publicly-traded landowners company, is the majority owner of Metaverse Group.
For further information please visit https://metaversegroup.com.
Brands or virtual landowners interested in partnering with Metaverse Group should contact Info@metaversegroup.com.
About Decentraland
Decentraland is the first fully decentralized virtual world. Powered by DAO, which owns the most important smart contracts and assets of Decentraland. Decentraland is software running on Ethereum that seeks to incentivize a global network of users to operate a shared virtual world. Decentraland users can buy and sell digital real estate, while exploring, interacting and playing games within this virtual world.
For further information please visit https://decentraland.org
About Tokens.com
Tokens.com Corp is a publicly-traded Web3 company that owns an inventory of metaverse, P2E, DeFi and NFT based digital assets. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in Play-to-Earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities on Twitter, LinkedIn, and YouTube.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220225005326/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ryleigh Ebron – Talk Shop Media
Email: mailto://ryleigh@talkshopmedia.com
NEWS -- Vivos Inc. Enhances its Intellectual Property Protection
Richland WA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to report that it filed its particle patent in several countries.
Our new patent team filed the particle patent in the USA, Canada, the European Union, Japan, Australia, Brazil, China, India, South Korea, and the Russian Eurasian (Russia, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Tajikistan, and Turkmenistan). Our patent counsel will also be pursuing amendments to increase the number of claims related to the particle patent.
In closing Dr. Korenko stated, “Intellectual property protect is always a priority and over time becomes increasingly important. Later this year we plan to submit a new utility patent for our hydrogel component. Our strategic plan is to use our intellectual property as a foundation for our exclusive licensing strategy in several regions in the world.”
About Vivos Inc. (OTCQB: RDGL)
Vivos Inc. has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals (IsoPet®) and in humans (RadioGel™). Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area using the company’s proprietary hydrogel technology. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers.
RadioGel™ is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.
RadioGel™ also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to family members.
The IsoPet® Solutions division used university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. Testing on feline sarcoma at the Washington State University was completed in 2018 and testing on canine soft tissue sarcomas at the University of Missouri was completed in 2019.
In 2018 the Company obtained confirmation from the FDA Center for Veterinary Medicine that IsoPet® is classified as a medical device according to its intended use and means by which it achieves its intended purpose. The FDA also reviewed the product labeling which included canine and feline sarcomas as the initial indications for use. The FDA does not require pre-market approval for veterinary devices so no additional approval is required. Following the demonstration phase, Vivos is able to generate revenue through the sale of IsoPet® to University animal hospitals and private veterinary clinics.
IsoPet® for treating animals uses the same technology as RadioGel™ for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.
CONTACT:
Vivos Inc.
Michael K. Korenko, Sc.D.
President & CEO
mailto://MKorenko@RadioGel.com
NEWS -- Tokens.com Tower Launched in Decentraland’s Crypto Valley
TORONTO, February 23, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in Web3 crypto assets and businesses linked to the Metaverse, NFTs and Crypto Gaming, is pleased to announce the completion of the Tokens.com Tower, a virtual office and event space in Decentraland’s Crypto Valley.
Tokens.com and its subsidiary companies, Metaverse Group and Hulk Labs will have their virtual headquarters located in the tower. The Tokens.com Tower is a multi-level virtual office space and conference center, located in Decentraland’s Crypto Valley. The tower overall represents the physical equivalent of over 28,000 square feet of usable office and event space that can host hundreds of virtual guests. A video of the tower can be viewed on the Tokens.com Youtube page (
NEWS -- Tokens.com Tower Launched in Decentraland’s Crypto Valley
TORONTO, February 23, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in Web3 crypto assets and businesses linked to the Metaverse, NFTs and Crypto Gaming, is pleased to announce the completion of the Tokens.com Tower, a virtual office and event space in Decentraland’s Crypto Valley.
Tokens.com and its subsidiary companies, Metaverse Group and Hulk Labs will have their virtual headquarters located in the tower. The Tokens.com Tower is a multi-level virtual office space and conference center, located in Decentraland’s Crypto Valley. The tower overall represents the physical equivalent of over 28,000 square feet of usable office and event space that can host hundreds of virtual guests. A video of the tower can be viewed on the Tokens.com Youtube page (
NEWS -- Tokens.com to Acquire 20% of Metaverse Architects
TORONTO, February 22, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in Web3 crypto assets and builds businesses linked to the Metaverse, NFTs and Play-to-Earn Gaming, is pleased to announce that its subsidiary, Metaverse Group(https://metaversegroup.com/), has signed a letter of intent to acquire 20% ownership interest in Metaverse Architects. In addition, Metaverse Group will appoint a representative to the board of directors of Metaverse Architects. The transaction is expected to close in March.
Metaverse Architects is a leading design and event planning firm who specialize in 3D modeling and game development. Metaverse Architects have the ability to design and build across several Metaverse worlds including Decentraland, Sandbox, Pax World and NFT Worlds. Additionally, the virtual architecture firm has the capability of hosting events and creating virtual immersive experiences for brands.
"We are pleased to combine forces with Metaverse Architects, the leading design and architecture firm in the Metaverse. Our partnership allows Metaverse Group to provide a host of services to our clients including events, NFT design and drops, and architecture design and services," said Andrew Kiguel, Tokens.com CEO and Executive Chairman of Metaverse Group. "We're excited to enhance the scope of what we offer with such a strong team to become a one-stop shop for all Metaverse needs."
Metaverse Architects is currently in the process of completing the Tokens.com Tower in Decentraland's Crypto Valley. The Tower will be used to host future crypto conferences and offer office rental spaces to companies looking for a presence in the Metaverse. Parties interested in developing a presence in the Metaverse on our property can contact mailto://Info@metaversegroup.com.
"Metaverse Group continues to not only acquire marquee properties, but also grow its list of services offered to retailers and advertisers. This collaboration enhances our ability to be the leading Metaverse real estate owner and developer," commented Metaverse Group CEO, Lorne Sugarman.
"Formalizing this partnership is an important step in ensuring we can continue expanding the quality and scope of our services, whilst ensuring we meet the sector’s growing demand. We’re confident that working together with Tokens.com and Metaverse Group will allow us to continue pioneering and trail-blazing in the Metaverse industry, whilst remaining at the forefront of Metaverse-based land design, utility development and Web 3.0 services," said Sean Ellul, Metaverse Architects Co-Founder.
About Metaverse Group
The Metaverse Group is a vertically integrated NFT based Metaverse real estate company. The group, with its global headquarters in Decentraland’s Crypto Valley, also owns an eight figure real estate portfolio across many leading virtual worlds. The company intends to continue to purchase, develop and rent out its portfolio of real estate assets. Tokens.com, a publicly- traded company, is the majority owner of Metaverse Group. The Metaverse Architects is a 3D Modeling & Game Development studio for the Metaverse. We design and develop for Decentraland, The Sandbox and all Metaverse worlds. Bringing your brand to the Virtual World in a playful and engaging way.
For further information please visit https://metaversegroup.com.
Brands or virtual land owners interested in partnering with Metaverse Group should contact: mailto://Info@metaversegroup.com.
About Metaverse Architects
Metaverse Architects are a 3D Modeling and Game Development studio for the Metaverse, who pioneer and develop immersion-focused use cases for brands and digital land owners in the Metaverse. With their slogan "If you can think it, we can build it!", Metaverse Architects are not afraid to push the boundaries of what is possible in Metaverse worlds, and work with a number of partners to develop new, cutting-edge use cases for brands which wish to expand their presence into the Metaverse.
For further information please visit: https://metaverse-architects.com/
About Tokens.com
Tokens.com Corp is a publicly traded Web3 company that owns an inventory of Metaverse, P2E, DeFi and NFT based digital assets and businesses. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in Play-to-Earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities at Twitter, LinkedIn, and YouTube.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220222005765/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ryleigh Ebron – Talk Shop Media
Email: mailto://ryleigh@talkshopmedia.com
NEWS -- Tokens.com to Acquire 20% of Metaverse Architects
TORONTO, February 22, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in Web3 crypto assets and builds businesses linked to the Metaverse, NFTs and Play-to-Earn Gaming, is pleased to announce that its subsidiary, Metaverse Group(https://metaversegroup.com/), has signed a letter of intent to acquire 20% ownership interest in Metaverse Architects. In addition, Metaverse Group will appoint a representative to the board of directors of Metaverse Architects. The transaction is expected to close in March.
Metaverse Architects is a leading design and event planning firm who specialize in 3D modeling and game development. Metaverse Architects have the ability to design and build across several Metaverse worlds including Decentraland, Sandbox, Pax World and NFT Worlds. Additionally, the virtual architecture firm has the capability of hosting events and creating virtual immersive experiences for brands.
"We are pleased to combine forces with Metaverse Architects, the leading design and architecture firm in the Metaverse. Our partnership allows Metaverse Group to provide a host of services to our clients including events, NFT design and drops, and architecture design and services," said Andrew Kiguel, Tokens.com CEO and Executive Chairman of Metaverse Group. "We're excited to enhance the scope of what we offer with such a strong team to become a one-stop shop for all Metaverse needs."
Metaverse Architects is currently in the process of completing the Tokens.com Tower in Decentraland's Crypto Valley. The Tower will be used to host future crypto conferences and offer office rental spaces to companies looking for a presence in the Metaverse. Parties interested in developing a presence in the Metaverse on our property can contact mailto://Info@metaversegroup.com.
"Metaverse Group continues to not only acquire marquee properties, but also grow its list of services offered to retailers and advertisers. This collaboration enhances our ability to be the leading Metaverse real estate owner and developer," commented Metaverse Group CEO, Lorne Sugarman.
"Formalizing this partnership is an important step in ensuring we can continue expanding the quality and scope of our services, whilst ensuring we meet the sector’s growing demand. We’re confident that working together with Tokens.com and Metaverse Group will allow us to continue pioneering and trail-blazing in the Metaverse industry, whilst remaining at the forefront of Metaverse-based land design, utility development and Web 3.0 services," said Sean Ellul, Metaverse Architects Co-Founder.
About Metaverse Group
The Metaverse Group is a vertically integrated NFT based Metaverse real estate company. The group, with its global headquarters in Decentraland’s Crypto Valley, also owns an eight figure real estate portfolio across many leading virtual worlds. The company intends to continue to purchase, develop and rent out its portfolio of real estate assets. Tokens.com, a publicly- traded company, is the majority owner of Metaverse Group. The Metaverse Architects is a 3D Modeling & Game Development studio for the Metaverse. We design and develop for Decentraland, The Sandbox and all Metaverse worlds. Bringing your brand to the Virtual World in a playful and engaging way.
For further information please visit https://metaversegroup.com.
Brands or virtual land owners interested in partnering with Metaverse Group should contact: mailto://Info@metaversegroup.com.
About Metaverse Architects
Metaverse Architects are a 3D Modeling and Game Development studio for the Metaverse, who pioneer and develop immersion-focused use cases for brands and digital land owners in the Metaverse. With their slogan "If you can think it, we can build it!", Metaverse Architects are not afraid to push the boundaries of what is possible in Metaverse worlds, and work with a number of partners to develop new, cutting-edge use cases for brands which wish to expand their presence into the Metaverse.
For further information please visit: https://metaverse-architects.com/
About Tokens.com
Tokens.com Corp is a publicly traded Web3 company that owns an inventory of Metaverse, P2E, DeFi and NFT based digital assets and businesses. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in Play-to-Earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities at Twitter, LinkedIn, and YouTube.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220222005765/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ryleigh Ebron – Talk Shop Media
Email: mailto://ryleigh@talkshopmedia.com
NEWS -- Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
Conference call and webcast to take place on Thursday, March 3, 2022, at 5:00 p.m. ET
SAN DIEGO, Calif. and CALGARY, AB, Feb. 22, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Thursday, March 3, 2022, at 5:00 p.m. ET to discuss a corporate update and financial results for the fourth quarter and full year 2021.
Conference Call & Webcast
Date: Thursday, March 3, 2022
Time: 5:00 p.m. Eastern Standard Time
Dial In – North American Toll-Free: (888) 664-6383
Dial In – International: (416) 764-8650
Conference ID (if needed): 4650-7590
Webcast: please click here
A webcast of the call will also be available on the Investor Relations page of Oncolytics' website, available by clicking here, and will be archived for three months. A dial in replay will be available for one week and can be accessed by dialing (888) 390-0541 (North America) or (416) 764-8677 (International) and using replay code: 507-590#.
About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards a registration study in metastatic breast cancer. For further information, please visit: https://www.oncolyticsbiotech.com.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the mode of action and potential and benefits of pelareorep as a cancer therapeutic; Oncolytics' plans to advance towards a registration study in metastatic breast cancer; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. In particular, we may be impacted by business interruptions resulting from COVID-19 coronavirus, including operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labour shortages, travel and shipping disruption, and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how Oncolytics may be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.
Company Contact
Jon Patton
Director of IR & Communication
+1-858-886-7813
mailto://jpatton@oncolytics.ca
Investor Relations for Oncolytics
Timothy McCarthy
LifeSci Advisors
+1-917-679-9282
mailto://tim@lifesciadvisors.com
Logo - https://mma.prnewswire.com/media/1064079/Oncolytics_Logo.jpg
View original content: https://www.prnewswire.com/news-releases/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-301486117.html
SOURCE Oncolytics Biotech® Inc.
NEWS -- Plus Therapeutics Partners with Medidata to Apply Innovative Synthetic Control Arm® Solution to Accelerate Brain Cancer Clinical Trial
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced a partnership with Medidata, a Dassault Systèmes company, to evaluate the use of its Synthetic Control Arm® (SCA) solution in a planned Phase 2 trial of Rhenium-186 NanoLiposome (186RNL) in recurrent glioblastoma (GBM), a type of brain cancer.
SCAs are especially advantageous in indications such as recurrent GBM where the standard of care control treatment is considered undesirable by some patients and physicians. The SCA enables study designs that have a higher than usual probability of assignment of prospective patients to the investigational therapy. This enhances patient enrollment and retention and potentially reduces clinical trial costs while upholding the scientific integrity of the trial.
“Medidata has developed a pioneering capability and helped to validate the use of synthetic controls in clinical drug development,” said Norman LaFrance, M.D., Chief Medical Officer and SVP of Plus Therapeutics. “Although a recent advancement, the U.S. Food and Drug Administration has already agreed to recognize a Phase 3 clinical trial design incorporating a synthetic control arm in a registrational randomized control arm in recurrent GBM.”
About the Synthetic Control Arm
Synthetic control arm – a type of external control – is formed by carefully selecting patients from Medidata’s extensive repository of historical clinical trials to match the baseline demographic and disease characteristics of the patients treated with the new investigational product. Case studies have shown that SCAs can effectively mimic a classic randomized control and, therefore, can be used to accurately interpret the treatment effects of an investigational product.
SCAs can help enhance the scientific validity of single-arm trials and, in certain indications, enhance randomized clinical trials to expose fewer prospective patients to control and/or ineffective or existing standard-of-care treatments that might not provide a benefit to the patient. This is done while still providing highly valid scientific evidence. These factors can influence a patient’s willingness to participate in a trial where there is a very poor prognosis and perceived inadequate standard of care.
About Plus Therapeutics
Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company focused on developing innovative, targeted radiotherapeutics for adults and children worldwide with rare and difficult-to-treat cancers. Our proprietary radiotherapeutic platform uniquely uses nanoliposomes to encapsulate and deliver the radioisotope, Rhenium, into or near a tumor via a single, direct infusion. The lead radiotherapeutic in our pipeline, Rhenium-186 NanoLiposome (186RNL), is being evaluated in U.S. multi-center clinical trials for the treatment of recurrent glioblastoma and leptomeningeal metastases. More information may be found at https://PlusTherapeutics.com and https://ReSPECT-Trials.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “designed to,” “will,” “can,” “potential,” “focus,” “preparing,” “next steps,” “possibly,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of 186RNL including the ability of 186RNL to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-LM or the ReSPECT-PBC trials; possible negative effects of 186RNL; the continued evaluation of 186RNL including through evaluations via a seventh patient cohort; and the intended functions of the Company’s platform and expected benefits from such functions.
The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the regenerative medicine field, among others; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Peter Vozzo
ICR Westwicke
(443) 377-4767
mailto://Peter.Vozzo@westwicke.com
Media Contact
Terri Clevenger
ICR Westwicke
(203) 856-4326
mailto://Terri.Clevenger@westwicke.com
NEWS -- Tokens.com Announces Change of Auditor
TORONTO, February 18, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or the "Company") announces that its board of directors (the "Board") has approved a change of the Company’s auditor. The Board and the Audit Committee of the Board have appointed Raymond Chabot Grant Thornton LLP (the "Incoming Auditor") as the Company’s new auditor, effective as of February 16, 2022. As a result, the Company’s former auditor, DNTW Toronto LLP (the "Former Auditor"), has submitted its resignation, effective February 16, 2022.
There were no disagreements or unresolved issues with the Former Auditor on any matter of the audit scope or procedures, accounting principles or policies, or financial statement disclosure. There have been no "reportable events" (as defined in National Instrument 51-102 – Continuous Disclosure Obligations) between the Company and the Former Auditor.
A Notice of Change of Auditor (the "Notice"), together with the response letters from the Former Auditor and Incoming Auditor have been reviewed by the Audit Committee and the Board and have been filed on https://www.sedar.com.
About Tokens.com
Tokens.com Corp is a publicly traded Web3 company that owns an inventory of Metaverse, Decentralized Finance ("DeFi"), Non-Fungible Tokens ("NFT") and Play-to-Earn Gaming ("P2E") based digital assets. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in P2E revenue generating tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
For further information please visit https://Tokens.com
Keep up-to-date on Tokens.com developments and join our online communities at Twitter, LinkedIn, and YouTube.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220218005282/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ryleigh Ebron – Talk Shop Media
Email: mailto://ryleigh@talkshopmedia.com
NEWS -- Tokens.com Announces Change of Auditor
TORONTO, February 18, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or the "Company") announces that its board of directors (the "Board") has approved a change of the Company’s auditor. The Board and the Audit Committee of the Board have appointed Raymond Chabot Grant Thornton LLP (the "Incoming Auditor") as the Company’s new auditor, effective as of February 16, 2022. As a result, the Company’s former auditor, DNTW Toronto LLP (the "Former Auditor"), has submitted its resignation, effective February 16, 2022.
There were no disagreements or unresolved issues with the Former Auditor on any matter of the audit scope or procedures, accounting principles or policies, or financial statement disclosure. There have been no "reportable events" (as defined in National Instrument 51-102 – Continuous Disclosure Obligations) between the Company and the Former Auditor.
A Notice of Change of Auditor (the "Notice"), together with the response letters from the Former Auditor and Incoming Auditor have been reviewed by the Audit Committee and the Board and have been filed on https://www.sedar.com.
About Tokens.com
Tokens.com Corp is a publicly traded Web3 company that owns an inventory of Metaverse, Decentralized Finance ("DeFi"), Non-Fungible Tokens ("NFT") and Play-to-Earn Gaming ("P2E") based digital assets. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in P2E revenue generating tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
For further information please visit https://Tokens.com
Keep up-to-date on Tokens.com developments and join our online communities at Twitter, LinkedIn, and YouTube.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220218005282/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ryleigh Ebron – Talk Shop Media
Email: mailto://ryleigh@talkshopmedia.com
NEWS -- Plus Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 24, 2022
AUSTIN, Texas, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report fourth quarter and full year 2021 financial results on Thursday, February 24, 2022, after market close. Plus Therapeutics’ management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update.
A live webcast will be available at https://ir.plustherapeutics.com/events
Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call.
Conference dial-in: 866-342-8591
International dial-in: 203-518-9713
Conference ID: PSTVQ421
Conference Call Name: Plus Therapeutics Fourth Quarter and Full Year 2021 Results Conference Call
Following the live call, a replay will be available on the Company’s website under the 'Investor Relations' section. The webcast will be available on the Company’s website for 90 days following the live call.
About Plus Therapeutics, Inc.
Plus Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative, targeted radiotherapeutics for adults and children worldwide with rare and difficult-to-treat cancers. Our proprietary radiotherapeutic platform uniquely uses nanoliposomes to encapsulate and deliver the radioisotope, Rhenium, into or near a tumor via a single, direct infusion. The lead radiotherapeutic in our pipeline, Rhenium-186 NanoLiposome (186RNL), is being evaluated in U.S. multi-center clinical trials for the treatment of recurrent glioblastoma and leptomeningeal metastases. More information may be found at https://PlusTherapeutics.com and https://ReSPECT-Trials.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “designed to,” “will,” “can,” “potential,” “focus,” “preparing,” “next steps,” “possibly,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of 186RNL including the ability of 186RNL to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-LM or the ReSPECT-PBC trials; possible negative effects of 186RNL; the continued evaluation of 186RNL including through evaluations via a seventh patient cohort; and the intended functions of the Company’s platform and expected benefits from such functions.
The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the regenerative medicine field, among others; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Peter Vozzo
ICR Westwicke
(443) 377-4767
mailto://Peter.Vozzo@westwicke.com
Media Contact
Terri Clevenger
ICR Westwicke
(203) 856-4326
mailto://Terri.Clevenger@westwicke.com
NEWS -- Provectus Biopharmaceuticals Announces Acceptance of PV-10® Metastatic Uveal Melanoma Abstract for Oral Presentation at 2022 International Society of Ocular Oncology (ISOO) Congress
KNOXVILLE, TN, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 for the treatment of uveal melanoma metastatic to the liver (mUM) (NCT00986661) will be presented at the 20th Congress of the International Society of Ocular Oncology (ISOO), to be held June 17-21, 2022 in Leiden, The Netherlands.
The abstract that was accepted for oral presentation is entitled:
NEWS -- Tokens.com Acquires Additional Metaverse Real Estate in Decentraland’s Fashion District
TORONTO, February 14, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in Web3 crypto assets linked to the Metaverse, Decentralized Finance ("DeFi"), Non-Fungible Tokens ("NFTs") and Play-to-Earn Gaming ("P2E"), is pleased to share that its subsidiary, Metaverse Group, has purchased an additional 49 parcels in Decentraland’s Fashion District.
The additional parcels are contiguous to the record breaking (https://www.nytimes.com/2021/11/30/business/metaverse-real-estate.html?smtyp=cur&smid=tw-nytimesf1b0a81f1dcf4b7/619ce382dfe9181d4e26460c_Tokens.com%20Announces%20Landmark%20Metaverse%20Purchase%20through%20its%20Subsidiary%2C%20Metaverse%20Group.docx.pdf) Fashion Street Estate that Metaverse Group purchased in 2021, and totals to the equivalent of over 132,000 square feet. In total, Metaverse Group owns the physical equivalent of approximately 450,000 square feet in Decentraland’s Fashion District.
"With the increased focus on fashion in the Metaverse, we are strategically increasing our ownership in the Fashion District of Decentraland through land that is contiguous to the land we own that is hosting Decentraland’s Fashion Week," said Andrew Kiguel, CEO of Tokens.com and Executive Chairman of Metaverse Group. "This purchase makes us the largest owner of contiguous property in the Fashion District. This is inline with our vision of building the marquee shopping area in the Metaverse to attract retailers and visitors."
Tokens.com’s Fashion Street Estate will be hosting Decentraland’s first ever virtual Fashion Week set to take place on March 24th to 27th. The event will feature catwalks, avatar supermodels, pop-up shops, afterparties and immersive visitor experiences.
"As we grow our portfolio of Metaverse real estate, we can provide better options, and more immersive experiences to support brands seeking to establish a presence," commented Lorne Sugarman, CEO of Metaverse Group.
About Metaverse Group
The Metaverse Group is a vertically integrated NFT based Metaverse real estate company. The group, with its global headquarters in Decentraland’s Crypto Valley, also owns an eight figure real estate portfolio across many leading virtual worlds. The company intends to continue to purchase, develop and rent out its portfolio of real estate assets. Tokens.com, a publicly- traded company, is the majority owner of Metaverse Group.
For further information please visit https://metaversegroup.com.
Brands or virtual land owners interested in partnering with Metaverse Group should contact: mailto://Info@metaversegroup.com.
About Decentraland
Decentraland is the first fully decentralized virtual world. Powered by DAO, which owns the most important smart contracts and assets of Decentraland. Decentraland is a software running on Ethereum that seeks to incentivize a global network of users to operate a shared virtual world. Decentraland users can buy and sell digital real estate, while exploring, interacting and playing games within this virtual world.
For further information please visit https://decentraland.org.
About Tokens.com
Tokens.com Corp is a publicly traded Web3 company that owns an inventory of Metaverse, P2E, DeFi and NFT based digital assets. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in Play-to-Earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities at Twitter, LinkedIn, and YouTube.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220214005151/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media:
Ryleigh Ebron – Talk Shop Media
Email: mailto://ryleigh@talkshopmedia.com
NEWS -- Tokens.com Acquires Additional Metaverse Real Estate in Decentraland’s Fashion District
TORONTO, February 14, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in Web3 crypto assets linked to the Metaverse, Decentralized Finance ("DeFi"), Non-Fungible Tokens ("NFTs") and Play-to-Earn Gaming ("P2E"), is pleased to share that its subsidiary, Metaverse Group, has purchased an additional 49 parcels in Decentraland’s Fashion District.
The additional parcels are contiguous to the record breaking (https://www.nytimes.com/2021/11/30/business/metaverse-real-estate.html?smtyp=cur&smid=tw-nytimesf1b0a81f1dcf4b7/619ce382dfe9181d4e26460c_Tokens.com%20Announces%20Landmark%20Metaverse%20Purchase%20through%20its%20Subsidiary%2C%20Metaverse%20Group.docx.pdf) Fashion Street Estate that Metaverse Group purchased in 2021, and totals to the equivalent of over 132,000 square feet. In total, Metaverse Group owns the physical equivalent of approximately 450,000 square feet in Decentraland’s Fashion District.
"With the increased focus on fashion in the Metaverse, we are strategically increasing our ownership in the Fashion District of Decentraland through land that is contiguous to the land we own that is hosting Decentraland’s Fashion Week," said Andrew Kiguel, CEO of Tokens.com and Executive Chairman of Metaverse Group. "This purchase makes us the largest owner of contiguous property in the Fashion District. This is inline with our vision of building the marquee shopping area in the Metaverse to attract retailers and visitors."
Tokens.com’s Fashion Street Estate will be hosting Decentraland’s first ever virtual Fashion Week set to take place on March 24th to 27th. The event will feature catwalks, avatar supermodels, pop-up shops, afterparties and immersive visitor experiences.
"As we grow our portfolio of Metaverse real estate, we can provide better options, and more immersive experiences to support brands seeking to establish a presence," commented Lorne Sugarman, CEO of Metaverse Group.
About Metaverse Group
The Metaverse Group is a vertically integrated NFT based Metaverse real estate company. The group, with its global headquarters in Decentraland’s Crypto Valley, also owns an eight figure real estate portfolio across many leading virtual worlds. The company intends to continue to purchase, develop and rent out its portfolio of real estate assets. Tokens.com, a publicly- traded company, is the majority owner of Metaverse Group.
For further information please visit https://metaversegroup.com.
Brands or virtual land owners interested in partnering with Metaverse Group should contact: mailto://Info@metaversegroup.com.
About Decentraland
Decentraland is the first fully decentralized virtual world. Powered by DAO, which owns the most important smart contracts and assets of Decentraland. Decentraland is a software running on Ethereum that seeks to incentivize a global network of users to operate a shared virtual world. Decentraland users can buy and sell digital real estate, while exploring, interacting and playing games within this virtual world.
For further information please visit https://decentraland.org.
About Tokens.com
Tokens.com Corp is a publicly traded Web3 company that owns an inventory of Metaverse, P2E, DeFi and NFT based digital assets. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in Play-to-Earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities at Twitter, LinkedIn, and YouTube.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220214005151/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media:
Ryleigh Ebron – Talk Shop Media
Email: mailto://ryleigh@talkshopmedia.com
New !
Does Ammpower have patents or pending patents on this green energy production unit, Does anyone know?
NEWS -- Tokens.com Acquires New Strategic Real Estate in Decentraland
TORONTO, February 08, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in Web3 crypto assets linked to the Metaverse, Decentralized Finance ("DeFi"), Non-Fungible Tokens ("NFTs") and Play-to-Earn Gaming ("P2E"), is pleased to share that its subsidiary, Metaverse Group (https://metaversegroup.com/), has successfully acquired three new strategic parcels in Decentraland. Consideration for the acquisition was equity in Metaverse Group. The vendor of the virtual land is JMD Capital.
The acquired virtual land is named The Gen Estate, a highly strategic plot that is located across from one of Decentraland’s transit centres, a hub that players use to navigate through the virtual world faster and is next to Dragon City, a virtual Chinese culture city built on the largest parcel in Decentraland. The real estate in this transaction is equivalent to nearly 25,000 square feet in physical terms. Metaverse Group plans to develop the land and rent it out to tenants.
"This transaction represents a valuable part of our strategy to not only purchase real estate but to use our equity to vend-in strategic partners. We believe we are amassing one of the most valuable portfolio’s of real estate in the Metaverse" commented Andrew Kiguel, CEO of Tokens.com.
About Metaverse Group
The Metaverse Group is a vertically integrated NFT based Metaverse real estate company. The group, with its global headquarters in Decentraland’s Crypto Valley, also owns an eight figure real estate portfolio across many leading virtual worlds. The company intends to continue to purchase, develop and rent out its portfolio of real estate assets. Tokens.com, a publicly- traded company, is the majority owner of Metaverse Group.
For further information please visit https://metaversegroup.com.
Brands or virtual land owners interested in partnering with Metaverse Group should contact: mailto://Info@metaversegroup.com.
About Tokens.com
Tokens.com Corp is a publicly traded Web3 company that owns an inventory of Metaverse, P2E, DeFi and NFT based digital assets. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in Play-to-Earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities at Twitter, LinkedIn, and YouTube.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220208005355/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ryleigh Ebron – Talk Shop Media
Email: mailto://ryleigh@talkshopmedia.com
NEWS -- Tokens.com Acquires New Strategic Real Estate in Decentraland
TORONTO, February 08, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or "the Company"), a publicly-traded company that invests in Web3 crypto assets linked to the Metaverse, Decentralized Finance ("DeFi"), Non-Fungible Tokens ("NFTs") and Play-to-Earn Gaming ("P2E"), is pleased to share that its subsidiary, Metaverse Group (https://metaversegroup.com/), has successfully acquired three new strategic parcels in Decentraland. Consideration for the acquisition was equity in Metaverse Group. The vendor of the virtual land is JMD Capital.
The acquired virtual land is named The Gen Estate, a highly strategic plot that is located across from one of Decentraland’s transit centres, a hub that players use to navigate through the virtual world faster and is next to Dragon City, a virtual Chinese culture city built on the largest parcel in Decentraland. The real estate in this transaction is equivalent to nearly 25,000 square feet in physical terms. Metaverse Group plans to develop the land and rent it out to tenants.
"This transaction represents a valuable part of our strategy to not only purchase real estate but to use our equity to vend-in strategic partners. We believe we are amassing one of the most valuable portfolio’s of real estate in the Metaverse" commented Andrew Kiguel, CEO of Tokens.com.
About Metaverse Group
The Metaverse Group is a vertically integrated NFT based Metaverse real estate company. The group, with its global headquarters in Decentraland’s Crypto Valley, also owns an eight figure real estate portfolio across many leading virtual worlds. The company intends to continue to purchase, develop and rent out its portfolio of real estate assets. Tokens.com, a publicly- traded company, is the majority owner of Metaverse Group.
For further information please visit https://metaversegroup.com.
Brands or virtual land owners interested in partnering with Metaverse Group should contact: mailto://Info@metaversegroup.com.
About Tokens.com
Tokens.com Corp is a publicly traded Web3 company that owns an inventory of Metaverse, P2E, DeFi and NFT based digital assets. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in Play-to-Earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.
Visit https://Tokens.com to learn more.
Keep up-to-date on Tokens.com developments and join our online communities at Twitter, LinkedIn, and YouTube.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220208005355/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ryleigh Ebron – Talk Shop Media
Email: mailto://ryleigh@talkshopmedia.com
NEWS -- CytoSorbents to Report Fourth Quarter and Full Year 2021 Operating and Financial Results
MONMOUTH JUNCTION, N.J., Feb. 8, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fourth quarter and full year 2021 operating and financial results after the market close on March 8, 2022. CytoSorbents' management will host a live conference call and presentation webcast at 4:30 p.m. Eastern the same day.
Conference call details:
Date: Tuesday, March 8, 2022
Time: 4:30 p.m. Eastern
Toll free: 1-877-451-6152
International: 1-201-389-0879
Conference ID: 13726520
The live audio webcast and presentation can be accessed via the following link : https://viavid.webcasts.com/starthere.jsp?ei=1525680&tp_key=7f828ec8e8
It is recommended that participants dial in approximately 10 minutes prior to the start of the call. An archived recording of the conference call will be available under the Investor Relations portion of the company's website at https://cytosorbents.com/investor-relations/financial-results/.
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification. Its flagship product, CytoSorb®, is approved in the European Union with distribution in more than 70 countries around the world as an extracorporeal cytokine adsorber designed to reduce the "cytokine storm" or "cytokine release syndrome" seen in common critical illnesses that may result in massive inflammation, organ failure and patient death. These are conditions where the risk of death can be extremely high, yet few to no effective treatments exist. CytoSorb is also being used during and after cardiothoracic surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. More than 162,000 cumulative CytoSorb devices have been utilized to date. CytoSorb was originally introduced into the European Union under CE-Mark as a first-in-kind cytokine adsorber. Additional CE-Mark label expansions were received for the removal of bilirubin and myoglobin in clinical conditions such as liver disease and trauma, respectively, and both ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with imminent or confirmed respiratory failure. The DrugSorb™-ATR Antithrombotic Removal System, which is based on the same polymer technology as CytoSorb, has also been granted FDA Breakthrough Designation for the removal of ticagrelor, as well as FDA Breakthrough Designation for the removal of the direct oral anticoagulant (DOAC) drugs, apixaban and rivaroxaban, in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery. The Company has initiated two FDA approved pivotal trials designed to support U.S. marketing approval of DrugSorb-ATR. The first is the 120-patient, 20 center STAR-T (Safe and Timely Antithrombotic Removal-Ticagrelor) randomized, controlled trial evaluating the ability of intraoperative DrugSorb-ATR use to reduce perioperative bleeding risk in patients on ticagrelor undergoing cardiothoracic surgery. The second is the 120-patient, 25 center STAR–D (Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants) randomized, controlled trial, evaluating the intraoperative use of DrugSorb–ATR to reduce perioperative bleeding risk in patients undergoing cardiothoracic surgery on direct oral anticoagulants, including apixaban and rivaroxaban.
CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of more than $39.5 million from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF/AFMC), and others. The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, DrugSorb™-ATR, ContrastSorb, and others. For more information, please visit the Company's websites at https://www.cytosorbents.com and https://www.cytosorb.com or follow us on Facebook and Twitter.
Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 9, 2021, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
Please Click to Follow Us on Facebook and Twitter
Investor Relations Contact:
Terri Anne Powers
Vice President, Investor Relations
and Corporate Communications
(732) 482-9984
mailto://tpowers@cytosorbents.com
U.S. Public Relations Contact:
Eric Kim
Rubenstein Public Relations
212-805-3052
mailto://ekim@rubensteinpr.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/cytosorbents-to-report-fourth-quarter-and-full-year-2021-operating-and-financial-results-301477298.html
SOURCE CytoSorbents Corporation
NEWS -- Provectus Biopharmaceuticals Announces Acceptance of PV-10® Systemic Administration Abstract at American Association for Cancer Research (AACR) Annual Meeting 2022
KNOXVILLE, TN, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical research on systemic administration of investigational cancer immunotherapy PV-10 (rose bengal sodium) for the treatment of high-risk and refractory adult solid tumor cancers will be presented at the annual meeting of the American Association for Cancer Research (AACR), to be held April 8-13, 2022 in New Orleans, Louisiana.
The abstract, which was accepted for poster presentation, is entitled:
NEWS -- Navidea Biopharmaceuticals Announces Research Agreement with the University of Pennsylvania Evaluating Tc99m Tilmanocept as a Prognostic Marker for Glioblastoma
DUBLIN, Ohio, February 07, 2022--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the signing of a Sponsored Research Agreement with the University of Pennsylvania ("Penn") for a project to evaluate the use of Tc99m tilmanocept imaging in glioblastoma as a prognostic agent for tumor growth rate and overall survival. The research is led by Principal Investigator Ali Nabavizadeh, MD, of the Department of Radiology in the Perelman School of Medicine at Penn.
Glioblastoma ("GBM") is the most aggressive and most common primary central nervous system tumor in adults and there is an urgent need for new therapies. Macrophages play an important role in tumor biology. They are a major population of non-cancer cells in GBM, representing as many as half of all cells in some cases. These Tumor Associated Macrophages ("TAMs") may then be a viable target for tumor therapies or serve as a biomarker for monitoring tumor status.
Broadly, active macrophages can be of a tumor suppressing type (M1 macrophages) or of a tumor promoting type (M2 macrophages). The TAMs are typically M2-like and are known to express high levels of CD206, the macrophage mannose receptor that Tc99m tilmanocept targets. This research has as its hypothesis that the M2 TAMs in GBM can be imaged with Tc99m tilmanocept, and that this imaging can serve as a predictive tool for outcome with and without use of an immunotherapy that works in part to change the M2-like macrophage population to a more M1-like state, promoting tumor killing.
In these preclinical studies, Tc99m tilmanocept imaging will be evaluated in correlation with tumor growth rate, and in separate studies Tc99m tilmanocept imaging will be performed before and after anti-interleukin-6 therapy, which has been shown to promote TAM switching from the M2 to M1 state. Study endpoints will include quantitative imaging compared to pathology and overall survival.
Dr. Michael Rosol, Chief Medical Officer for Navidea, said, "We are pleased to sponsor this important work with Dr. Nabavizadeh at Penn. This is another in a line of research collaborations we have had with the highest level of researchers at top tier institutions." Dr. Rosol continued, "Today’s announcement exemplifies the broad reach of our tilmanocept platform. The development of applications of Tc99m tilmanocept as a prognostic biomarker in cancers could have far-reaching implications for monitoring patient treatment and making decisions about therapeutic benefit. We are excited to continue to develop new and valuable applications for our core technology."
"TAMs are a very important component of immune microenvironment in GBM, and it is crucial to have reliable imaging biomarkers to quantify and monitor TAMs during the course of treatment," Dr. Nabavizadeh said. "The advantage of Tc99m tilmanocept is that it is already being used in patients for another research indication which means that we can move forward to human GBM patients under an Investigational New Drug Application (IND) if our preclinical studies show promising results."
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept™ platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, please visit https://www.navidea.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements include our expectations regarding pending litigation and other matters. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: our history of operating losses and uncertainty of future profitability; the final outcome of any pending litigation; our ability to successfully complete research and further development of our drug candidates; the timing, cost and uncertainty of obtaining regulatory approvals of our drug candidates; our ability to successfully commercialize our drug candidates; dependence on royalties and grant revenue; our ability to implement our growth strategy; anticipated trends in our business; our limited product line and distribution channels; advances in technologies and development of new competitive products; our ability to comply with the NYSE American continued listing standards; our ability to maintain effective internal control over financial reporting; the impact of the current coronavirus pandemic; and other risk factors detailed in our most recent Annual Report on Form 10-K and other SEC filings. You are urged to carefully review and consider the disclosures found in our SEC filings, which are available at www.sec.gov or at http://ir.navidea.com.
Investors are urged to consider statements that include the words "will," "may," "could," "should," "plan," "continue," "designed," "goal," "forecast," "future," "believe," "intend," "expect," "anticipate," "estimate," "project," and similar expressions, as well as the negatives of those words or other comparable words, to be uncertain forward-looking statements.
You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be incorrect. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this report. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220207005162/en/
Contacts
Investor Relations Contact
Navidea Biopharmaceuticals, Inc.
Jeffrey Smith
Vice President of Operations
614-822-2365
mailto://jsmith@navidea.com
NEWS -- Plus Therapeutics to Present at BIO CEO & Investor Conference
AUSTIN, Texas, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics, will present a company overview during the BIO CEO & Investor Conference on Monday, February 14, 2022 at 1:15 p.m. ET, at the New York Marriott Marquis.
The Company’s live presentation will be made available through the BIO CEO & Investor Conference website and available on-demand to registered participants during the conference at https://www.bio.org/events/bio-ceo-investor-conference/sessions. Investors interested in arranging a meeting with the Company’s management for this conference should contact the conference coordinator.
About Plus Therapeutics
Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company focused on developing innovative, targeted radiotherapeutics for adults and children worldwide with rare and difficult-to-treat cancers. Our proprietary radiotherapeutic platform uniquely uses nanoliposomes to encapsulate and deliver the radioisotope, Rhenium, into or near a tumor via a single, direct infusion. The lead radiotherapeutic in our pipeline, Rhenium-186 NanoLiposome (186RNL), is being evaluated in U.S. multi-center clinical trials for the treatment of recurrent glioblastoma and leptomeningeal metastases. More information may be found at https://PlusTherapeutics.com and https://ReSPECT-Trials.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “designed to,” “will,” “can,” “potential,” “focus,” “preparing,” “next steps,” “possibly,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of 186RNL including the ability of 186RNL to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-LM or the ReSPECT-PBC trials; possible negative effects of 186RNL; the continued evaluation of 186RNL including through evaluations via a seventh patient cohort; and the intended functions of the Company’s platform and expected benefits from such functions.
The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the regenerative medicine field, among others; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Peter Vozzo
ICR Westwicke
(443) 377-4767
mailto://Peter.Vozzo@westwicke.com
Media Contact
Terri Clevenger
ICR Westwicke
(203) 856-4326
mailto://Terri.Clevenger@westwicke.com